Health ProductsDear Healthcare Professional Letter

Archived - For Health Professionals - Possible Association of Remicade (infliximab) with hepatosplenic T-cell lymphoma in pediatric and young adult patients with Crohn's disease

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Biologic/vaccine, Affects children, pregnant or breast feeding women
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Schering Canada, Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on Remicade (infliximab)

July 24, 2006

Subject: Possible Association of REMICADE® with hepatosplenic T-cell lymphoma in pediatric and young adult patients with Crohn's disease

Dear Health Care Professional,

Centocor, Inc. and Schering Canada, Inc., in consultation with Health Canada, would like to inform you of important new safety information regarding REMICADE® (infliximab).

REMICADE® (infliximab) is a chimeric IgG monoclonal antibody known as a Biological Response Modifier that is directed against the cytokine tumour necrosis factor-α(TNFα). It is indicated for the treatment of adults with rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis, and chronic plaque psoriasis.

  • REMICADE® is not authorized for pediatric use in Canada.
  • Six (6) post-marketing cases of a rare type of lymphoma called hepatosplenic T-cell lymphoma (HSTCL) have been reported in pediatric and young adult patients taking REMICADE® for Crohn's disease.
  • Exposure to REMICADE® ranged from 1 or 2 infusions to over 4 years of maintenance therapy, and five of the six cases resulted in death.
  • All cases reported concomitant or past use of other immunosuppressive agents, including azathioprine or 6-mercaptopurine. As a result, a causal relationship between REMICADE® and the development of HSTCL has not been clearly established.

The six reports of HSTCL in Crohn's disease patients documented ages ranging from 12 to 31 years, with five of the cases occurring in patients aged 12 to 19. Four of the six cases occurred in males. All reports originated from the United States, and one report was recently published in the literature.1

This disease is a very rare form of non-Hodgkin's lymphoma (NHL), which occurs most commonly in adolescent and young adult males, and there are only 150 cases published in the medical literature worldwide since the disease was first described in 1990.2 The disease usually presents as marked hepatosplenomegaly with bone marrow involvement and cytopenia, most commonly thrombocytopenia. Patients may have symptoms characteristic of B-cell lymphomas with fever, weight loss, and night sweats, but without lymphadenopathy or significant peripheral blood lymphocytosis. The clinical course of the disease is extremely aggressive, with a fatal outcome in most patients within 2 years of diagnosis.

Both azathioprine and 6-mercaptopurine are known mutagens, and azathioprine has been classified as a human carcinogen.3 There have also been three reports in the literature of HSTCL occurring in Crohn's disease patients receiving these drugs without REMICADE®.4, 5, 6 Because all cases described concomitant or past use of such agents, a causal association between REMICADE® and HSTCL has not been clearly established. However, a role for REMICADE® in causing or exacerbating this disease cannot be excluded.

In Canada, approximately 38,000 patients have received REMICADE® since its launch in 2001, with 16,000 patients having received the product for Crohn's disease. Although lymphomas have been reported in Canada in patients receiving REMICADE® for Crohn's disease and other indications, there have been no reports of HSTCL.

Information regarding the risk of lymphoma in patients receiving REMICADE® was also previously communicated to Canadian healthcare professionals in 2004.7

REMICADE® is only authorized in Canada for the treatment of adult patients. The Canadian Product Monograph for REMICADE® is being revised to include the above updated safety information.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any occurrences of serious and/or unexpected adverse reactions in patients receiving REMICADE® (infliximab) should be reported to Schering Canada, Inc., or Health Canada, at the following addresses:

Schering Canada, Inc.
3535 Trans-Canada Highway
Pointe Claire, Quebec, H9R 1B4
Tel: (800) 463-5442
Fax: (800) 369-3090

Any suspected adverse incident can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: (613) 954-6522
Fax: (613) 952-7738

Sincerely,

original signed by

Dr. Nabil Abadir
Director, Medical Research
Schering Canada, Inc.

  1. Thayu M et al. 2005. Hepatosplenic T-Cell Lymphoma in an Adolescent Patient after Immunomodulator and Biologic Therapy for Crohn Disease. J. Pediatr Gastroenterol Nutr. 40:220-222.
  2. Farcet JP et al. 1990. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma-delta. Blood. 75: 2213-2219.
  3. World Health Organization International Agency for Research on Cancer (IARC), IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 1981. 26:47. Available at the following link: http://monographs.iarc.fr/ENG/Monographs/vol26/volume26.pdf.
  4. Mittal MS et al. 2006. A case of hepatosplenic γδ T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol. 76: 531-534.
  5. Navarro JT et al. 2003. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma. 44: 531-533.
  6. Lemann M et al. 1998. Intravenous cyclosporine for refractory attacks of Crohn's disease (CD): long-term follow-up of patients [abstract]. Gastroenterology. 114 (number 4, part 2): A1020.
  7. Health Professional Communication: Updated Safety Information addressing the risk of malignancies associated with REMICADE (infliximab). November 29, 2004. Link: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2004/remicade_2_hpc-cps-eng.php
Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime